Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11043190 | 0.86 | CD44 (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7550920 | 0.86 | CD44 (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9918976 | 0.86 | CD44 (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8860053 | 0.86 | CD44 (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL762587 | 0.80 | KDM1A (0.39) | CD44CYP3A4LMNAPOLBAPEX1 | |
| SCHEMBL5390700 | 0.79 | CD44 (0.65) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL20182545 | 0.79 | CD44 (0.41) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL18617511 | 0.79 | LMNA (0.52) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6722803 | 0.79 | KDM1A (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL363712 | 0.79 | KDM1A (0.44) | CD44GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103996872-A | Lithium ion battery non-aqueous electrolyte with functions of overcharging prevention and flame retardancy | ZHUHAI SMOOTHWAY ELECTRONIC MATERIALS CO LTD | 2014-08-20 | — | — | CN | claimed |
| EP-1094053-B1 | Method of preparing fluoroaromatic compounds | ZELINSKY INST OF ORGANIC CHEMI (RU) | 2003-05-21 | — | — | EP | claimed |
| EP-1094053-A1 | Method of preparing fluoroaromatic compounds | Zelinsky Institute of Organic Chemistry (RU) | 2001-04-25 | — | — | EP | claimed |
| US-6008407-A | REACTING CHLOROTRIFLUOROETHYLENE AND 1,3-BUTADIENE TO PRODUCE CHLOROTRIFLUOROCYCLOHEXENES, DEHYDROHALOGENATING THE MIXTURE OF CYCLOHEXENES WITH PHASE TRANSFER CATALYST IN PRESENCE OF ALKALI METAL HYDROXIDE WITHOUT SOLVENT | ZELINSKY INSTITUTE OF ORGANIC CHEMISTRY (RU) | 1999-12-28 | — | — | US | claimed |
| WO-2023200441-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023196454-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | disclosed |
| US-9458155-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9433626-B2 | Pyrido[4,3-B]indole and pyrido[3,4-B]indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150335654-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150259344-A1 | IMIDAZOLE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-09-17 | — | — | US | disclosed |
| US-20150051218-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2005030796-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1094053-B1 | Method of preparing fluoroaromatic compounds | ZELINSKY INST OF ORGANIC CHEMI (RU) | 2003-05-21 | — | — | EP | disclosed |
| EP-1094053-A1 | Method of preparing fluoroaromatic compounds | Zelinsky Institute of Organic Chemistry (RU) | 2001-04-25 | — | — | EP | disclosed |
| EP-1094053-A1 | Method of preparing fluoroaromatic compounds | Zelinsky Institute of Organic Chemistry (RU) | 2001-04-25 | — | — | EP | disclosed |
| US-6008407-A | REACTING CHLOROTRIFLUOROETHYLENE AND 1,3-BUTADIENE TO PRODUCE CHLOROTRIFLUOROCYCLOHEXENES, DEHYDROHALOGENATING THE MIXTURE OF CYCLOHEXENES WITH PHASE TRANSFER CATALYST IN PRESENCE OF ALKALI METAL HYDROXIDE WITHOUT SOLVENT | ZELINSKY INSTITUTE OF ORGANIC CHEMISTRY (RU) | 1999-12-28 | — | — | US | disclosed |
| US-6008407-A | REACTING CHLOROTRIFLUOROETHYLENE AND 1,3-BUTADIENE TO PRODUCE CHLOROTRIFLUOROCYCLOHEXENES, DEHYDROHALOGENATING THE MIXTURE OF CYCLOHEXENES WITH PHASE TRANSFER CATALYST IN PRESENCE OF ALKALI METAL HYDROXIDE WITHOUT SOLVENT | ZELINSKY INSTITUTE OF ORGANIC CHEMISTRY (RU) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051218-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | CD44 3749/4885GRIN2D 19/4885GRIN3B 28/4885 |
| US-20150259344-A1 | IMIDAZOLE DERIVATIVE | CHRNA4, CHRNB4, CHRNA7 | CD44 3143/4885GRIN2D 383/4885GRIN3B 135/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | CD44 4823/4885GRIN2D 4477/4885GRIN3B 3622/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | CD44 2570/4885GRIN2D 65/4885GRIN3B 75/4885 |
| US-20150335654-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CD44 4393/4885GRIN2D 25/4885GRIN3B 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.